ERBB2 and breast cancer: Thus, we investigated EDI3’s potential clinical relevance using publicly available data, as well as our own breast cancer patient cohorts, and show that EDI3 expression is highest in estrogen receptor (ESR1)-negative (ER-) HER2 + tumours.